Figure 1A

Anti-IFNAR 3F11 VH

```
          Q   V   Q   L   Q   Q   W   G   A   G   L   L   K   P   S   E   T   L
  1      CAG GTG CAG CTA CAG CAG TGG GGC GCA GGA CTG TTG AAG CCT TCT GAC ACC CTG

                                                                    CDR1
                                                              ~~~~~~~~~~~~~~~~~~~
          S   L   T   C   A   V   Y   G   G   S   F   S   G   Y   F   W   S   W
 55      TCC CTC ACC TGC GCT GTC TAT GGT GGG TCC TTC AGT GGT TAT TTC TGG AGC TGG

                                                                        CDR2
                                                                  ~~~~~~~~~~~~~~~~~
          I   R   Q   P   P   G   K   G   L   E   W   I   G   E   I   D   H   S
109      ATC CGC CAG CCC CCA GGG AAG GGG CTG GAG TGG ATT GGG GAA ATC GAT CAC AGT

                     CDR2
         ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
          G   K   T   N   Y   N   P   S   L   K   S   R   V   T   I   S   V   D
163      GGA AAG ACC AAC TAC AAT CCG TCC CTC AAG AGT CGA GTT ACC ATA TCA GTA GAC

          T   S   K   N   Q   V   S   L   K   L   S   S   V   T   A   A   D   T
217      ACG TCC AAG AAC CAG GTC TCC CTG AAG CTG AGC TCT GTG ACC GCC GCG GAC ACG

                                                          CDR3
                                             ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
          A   V   Y   Y   C   A   R   E   S   K   Y   Y   F   G   L   D   V   W
271      GCT GTG TAT TAC TGT GCG AGA GAA AGC AAG TAC TAC TTC GGT TTG GAC GTC TGG

          G   Q   G   T   T   V   T   V   T   S
325      GGC CAA GGG ACC ACG GTC ACC GTC ACC TCA
```

Figure 1B

Anti-IFNAR 3F11 VK

```
      A   I   Q   L   T   Q   S   P   S   S   L   S   A   S   V   G   D   R
1     GCC ATC CAG TTG ACC CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA GGA GAC AGA

                              CDR1
                              ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
      V   T   I   T   C   R   A   S   Q   G   I   Y   S   V   L   A   W   Y
55    GTC ACC ATC ACT TGC CGG GCA AGT CAG GGC ATT TAC AGT GTT TTA GCC TGG TAT

                                                      CDR2
                                                      ~~~~~~~~~~~~~~~~~~
      Q   Q   K   P   G   K   T   P   K   L   L   I   Y   D   A   S   R   L
109   CAG CAG AAA CCA GGG AAA ACT CCT AAG CTC CTG ATC TAT GAT GCC TCC CGT TTG


      CDR2
      ~~~~~~~~
      E   S   G   V   P   S   R   F   S   G   S   G   S   G   T   D   F   T
163   GAA AGT GGG GTC CCA TCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAT TTC ACT

                                                                  CDR3
                                                                  ~~~~~~~
      L   T   I   S   S   L   Q   P   E   D   F   A   T   Y   Y   C   Q   Q
217   CTC ACC ATC AGC AGC CTG CAG CCT GAA GAT TTT GCA ACT TAT TAC TGT CAA CAG

              CDR3
              ~~~~~~~~~~~~~~~~~~~~~~~~~
      F   N   S   Y   I   T   F   G   Q   G   T   R   L   E   I   K
271   TTT AAT AGT TAC ATC ACC TTC GGC CAA GGG ACA CGA CTG GAG ATT AAA
```

Figure 2A

Anti-IFNAR 4G5 VH



	Q	V	Q	L	Q	Q	W	G	A	G	L	L	K	P	S	E	T	L
1	CAG	GTG	CAG	CTA	CAG	CAG	TGG	GGC	GCA	GGA	CTG	TTG	AAG	CCT	TCG	GAG	ACC	CTG
	S	L	T	C	A	V	Y	G	G	S	F	S	N	Y	Y	W	S	W
55	TCC	CTC	ACC	TGC	GCT	GTC	TAT	GGT	GGG	TCC	TTC	AGT	AAT	TAC	TAC	TGG	AGC	TGG
	I	R	Q	P	P	G	K	G	L	E	W	I	G	E	I	I	L	S
109	ATC	CGC	CAG	CCC	CCA	GGG	AAG	GGG	CTG	GAG	TGG	ATT	GGG	GAA	ATC	ATT	CTT	AGT
	G	S	T	N	Y	N	P	S	L	K	S	R	V	T	I	S	V	D
163	GGA	AGC	ACC	AAC	TAC	AAC	CCG	TCC	CTC	AAG	AGT	CGA	GTC	ACC	ATA	TCA	GTA	GAC
	T	S	K	N	Q	F	S	L	N	L	T	S	V	T	A	A	D	T
217	ACG	TCC	AAG	AAC	CAG	TTC	TCC	CTG	AAC	CTG	ACC	TCT	GTG	ACC	GCC	GCG	GAC	ACG
	A	Y	Y	Y	C	A	R	E	S	K	W	G	Y	Y	F	D	S	W
271	GCT	GTG	TAT	TAC	TGT	GCG	AGA	GAG	TCT	AAA	TGG	GGT	TAC	TAC	TTT	GAC	TCC	TGG
	G	Q	G	T	L	V	T	V	S	S								
325	GGC	CAG	GGA	ACC	CTG	GTC	ACC	GTC	TCC	TCA								

Anti-IFNAR 4G5 VK

Figure 2B




Figure 3A

Anti-IFNAR 11E2 VH

```
      E   V   Q   L   V   Q   S   G   A   E   V   K   K   P   G   E   S   L
1     GAG GTG CAG CTG GTG CAG TCT GGA GCA GAG GTG AAA AAG CCC GGG GAG TCT CTG

                                                        CDR1
                                                    ~~~~~~~~~~~~~~~~~~~~
      K   I   S   C   K   G   S   G   Y   I   F   T   N   Y   W   I   A   W
55    AAG ATC TCC TGT AAG GGT TCT GGA TAC ATC TTT ACC AAT TAC TGG ATC GCC TGG

                                                            CDR2
                                                    ~~~~~~~~~~~~~~~~~~~~
      V   R   Q   M   P   G   K   G   L   E   S   M   G   I   I   Y   P   G
109   GTG CGC CAG ATG CCC GGT AAA GGC CTG GAG TCG ATG GGG ATC ATC TAT CCT GGT

                        CDR2
      ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
      D   S   D   I   R   Y   S   P   S   F   Q   G   Q   V   T   I   S   A
163   GAC TCT GAT ATC AGA TAC AGC CCG TCC TTC CAA GGC CAG GTC ACC ATC TCA GCC


      D   K   S   I   T   T   A   Y   L   Q   W   S   S   L   K   A   S   D
217   GAC AAG TCC ATC ACC ACC GCC TAC CTG CAG TGG AGC AGT CTG AAG GCC TCA GAC

                                                CDR3
                                            ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
      T   A   M   Y   Y   C   A   R   H   D   I   E   G   F   D   Y   W   G
271   ACC GCC ATG TAT TAC TGT GCG AGA CAT GAC ATA GAG GGG TTT GAC TAC TGG GGC

      R   G   T   L   V   T   V   S   S
325   CGG GGA ACC CTG GTC ACC GTC TCC TCA
```

Anti-IFNAR 11E2 VK

Figure 3B



Anti-IFNAR 9D4 VH

Figure 4A

```
      E   V   Q   L   V   Q   S   G   A   E   V   K   K   P   G   E   S   L
1     GAG GTG CAG CTG GTG CAG TCT GGA GCA GAG GTG AAA AAG CCC GGG GAG TCT CTG

                                                      CDR1
                                                      ~~~~~~~~~~~~~~~~~~~~
      K   I   S   C   K   G   S   G   Y   I   F   T   N   Y   W   I   A   W
55    AAG ATC TCC TGT AAG GGT TCT GGA TAC ATC TTT ACC AAC TAC TGG ATC GCC TGG

                                                          CDR2
                                                          ~~~~~~~~~~~~~~~~~~
      V   R   Q   M   P   G   K   G   L   E   S   M   G   I   I   Y   P   G
109   GTG CGC CAG ATG CCC GGT AAA GGC CTG GAG TCG ATG GGG ATC ATC TAT CCT GGT

                                CDR2
                                ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
      D   S   D   I   R   Y   S   P   S   F   Q   G   Q   V   T   I   S   A
163   GAC TCT GAT ATC AGA TAC AGC CCG TCC TTC CAA GGC CAG GTC ACC ATC TCA GCC

      D   K   S   I   T   T   A   Y   L   Q   W   S   S   L   K   A   S   D
217   GAC AAG TCC ATC ACC ACC GCC TAC CTG CAG TGG AGC AGT CTG AAG GCC TCA GAC

                                                  CDR3
                                                  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~
      T   A   M   Y   Y   C   A   R   H   D   I   E   G   F   D   Y   W   G
271   ACC GCC ATG TAT TAC TGT GCG AGA CAT GAC ATA GAG GGG TTT GAC TAC TGG GGC


      R   G   T   L   V   T   V   S   S
325   CGG GGA ACC CTG GTC ACC GTC TCC TCA
```

Figure 4B

Anti-IFNAR 9D4 VK




Figure 5



ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT IgG1-unmodified
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT IgG1-modified
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT IgG4-modified
ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT IgG4-unmodified
(228)
(234)
(235)
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP IgG1-unmodified
VPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTP IgG1-modified
VPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG---PPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTP IgG4-modified
VPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG---PPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTP IgG4-unmodified
EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA IgG1-unmodified
EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA IgG1-modified
EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG IgG4-modified
EVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG IgG4-unmodified
(331)
LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV IgG1-unmodified
LPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV IgG1-modified
LPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV IgG4-modified
LPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV IgG4-unmodifed
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK. IgG1-unmodified
LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK. IgG1-modified
LDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK. IgG4-modified
LDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK IgG4-unmodified

Figure 6A

Human cerebrum




Figure 6B



MDX-1333 50 µg/ml
9D4 50 µg/ml
4G5 20 µg/ml
MDX-1333 20 µg/ml
9D4 20 µg/ml
R3-47 50 µg/ml
Mouse macs MDX-1333
50 µg/ml
10µm

Figure 7



Untreated
IFN only
IFN + R347
IFN + 9D4
pY701 Stat1
Total Stat1
pS727 Stat3
Total Stat3
pY694 Stat5
Total Stat5

Figure 8

Donor #190

9D4

Type-I IFN concentration (IU/mL)	IC_{50}(nM)	Percent Inhibition*
50	0.005	97
100	0.008	98
500	0.04	98
1000	0.06	99
2000	0.16	99
5000	0.5	98

Donor #141

9D4

Type-I IFN concentratio (IU/mL)	IC_{50}(nM)	Percent Inhibition*
50	0.02	99.1
100	0.04	99
500**	0.2	98.6
1000	0.2	98
2000**	0.9	100
5000**	2.4	100

Donor #237

9D4

Type-I IFN concentration (IU/mL)	IC_{50}(nM)	Percent Inhibition*
50	0.008	99
100	0.01	99
500	0.04	99
1000	0.09	98
2000	0.12	99
5000	0.65	96

Figure 9



A
9D4-wt
cps (Europium)
10000
7500
5000
2500
0
0
1
2
3
4
9D4-IgG1Eu (nM)
KD = 0.06 +/- 0.02 nM
IFNAR1 sites = 7038 +/- 727

Figure 9 continued




Figure 9



C
9D4-TM
Europium cps
17500
15000
12500
10000
7500
5000
2500
0
0.0
0.5
1.0
1.5
2.0
2.5
9D4-IgG1 TM^{Eu} (nM)
K_D = 0.03 +/- 0.01 nM
IFNAR1 sites = 13367 +/- 487

Figure 10A




1 pM IgG curve
10 pM IgG curve
30 pM IgG curve
% Free 9D4
110%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0
-10%
1.00E-14
1.00E-12
1.00E-10
1.00E-08
[sIFNαR1]

Figure 10B



Kd (nM)	Bmax (cps)
0.29+/-0.11	1448+/-447

Figure 11




293H-ISRE luminescence (cps)
60000
50000
40000
30000
20000
10000
0
-6
-5
-4
-3
-2
-1
0
1
2
Antibody concentration
9D4 WT (IC50 = 0.01nM)
9D4 DM (IC50 = 0.01nM)
9D4 TM triple (IC50 = 0.02nM)
MDX1333 (IC50 = 0.04nM)
R3-47 (IgG1 isotype control)

Figure 12A



A.9D4
B.9D4-TM
C.9D4-DM

Figure 12B



9D4 DM
9D4
9D4 TM
70.41
70.88
70.41
0.0003
0.0002
0.0001
0.0000
-0.0001
-0.0002
Cp(cal/°C)
20
40
60
80
100
120
Temperature (°C)

Figure 13



Adv-control
Adv-IFNα
Adv-IFNα + MuIgG
Adv-IFNα + a-IFNAR
Mice w/o Proteinuria (%)
120
100
80
60
40
20
0
0
1
2
3
4
5
6
7
8
9
Time (week)

Figure 14



IFIT1
IF144
CXCL11
IFI202b
CXCL10
CXCL9
Fold Change
PBS
Adv
MuIgG
dNFAR
Adv-IFNα
*
**

Figure 15



A
Anti-dsDNA (μg/ml)
240
180
120
60
0
Adv
PBS
MuIgG
a-IFNAR
Adv-IFNα
*
B
Anti-SSA/Ro (μg/ml)
60
40
20
0
Adv
PBS
MuIgG
a-IFNAR
Adv-IFNα
*

Figure 16



A
IP-10 (pg/g kidney)
600
500
400
300
200
100
0
PBS
Adv
MuIgG
a-IFNAR
Adv-IFNα5
*
B
IL-18 (pg/g kidney)
3500
3000
2500
2000
1500
1000
500
0
PBS
Adv
MuIgG
a-IFNAR
Adv-IFNα5
*

Figure 17



Serum ANA titer
1:64
1:32
1:16
1:8
Balb/C
Adv
PBS
MuIgG
a-IFNAR
Adv-IFNα
*

Figure 18

Exp. #	CD38, % max suppression	IC50 nM	CD123, % max. suppression	IC50 nM
1	88%	0.05	NC	NC
2	100%	0.05	70%	0.06
3	81%	0.02	64%	0.04
4	91%	0.04	76%	0.06
5	NC	NC	72%	0.06
NC: not calculated (no induction).				

Figure 19



CD38
% of suppression
70
60
50
40
30
20
10
0
-6
-5
-4
-3
-2
-1
0
1
log10 [Ab] (ug/ml)
9D4 IgG1 Parental IC50 = 4.3 ng/ml.
9D4 IgG4 Double Mutant IC50 = 40 ng/ml.
9D4 IgG1 Triple Mutant IC50 = 25 ng/ml.
A

Figure 19 continued




Figure 19 continued




Figure 20



9D4 WT
9D4 TM
9D4 DM
Control Antibody
OD at 450 nM
2.5
2.0
1.5
1.0
0.5
0.0
0.01
0.1
1
10
100
1000
IgG (ug/ml)

Figure 21A



9D4WT
FcrRIIIA-10
FcrRIIIA-10 F158V
OD at 450 nm
0.220
0.195
0.170
0.145
0.120
0.095
0.070
0.045
0
1
2
3
4
5
6
CD16 (Log ng/ml)

Figure 21B



9D4DM
FcrRIIIA-10
FcrRIIIA-10 F158V
OD at 450 nM
0.105
0.095
0.085
0.075
0.065
0.055
0.045
0.035
0
1
2
3
4
5
CD16 (Log ng/ml)

Figure 21C



9D4TM
FcrRIIIA-10
FcrRIIIA-10 F158V
OD at 450 nM
0.105
0.095
0.085
0.075
0.065
0.055
0.045
0
1
2
3
4
5
6
CD16 (Log ng/ml)

Figure 22A



9D4 wt
FcrRIIIA-10
FcrRIIIA-10 F158V
OD at 450 nM
0.105
0.095
0.085
0.075
0.065
0.055
0.045
0
1
2
3
4
5
6
CD16 (Log ng/ml)

Figure 22B



9D4DM
FcrRIIIA-10
FcrRIIIA-10 F158V
OD at 450 nM
0.105
0.095
0.085
0.075
0.065
0.055
0.045
0
1
2
3
4
5
6
CD16 (Log ng/ml)

Figure 22C



9D4TM
FcrRIIIA-10
FcrRIIIA-10 F158V
OD at 450 nM
0.105
0.095
0.085
0.075
0.065
0.055
0.045
0
1
2
3
4
5
6
CD16 (Log ng/ml)

Figure 23



A
IFNα C/10
% IFN Neutralization
110
100
90
80
70
60
50
40
30
20
10
0
-10
0.0001
0.0007
0.001
0.01
0.1
1
10
100
1000
Ab ug/ml
MDX1333
9D4TM
9D4WT
HuIgG1

Figure 23 continued




Figure 23 continued




Figure 23 continued




Figure 24



PIL6-ISRE Luminescence (cps)
13000
12000
11000
10000
9000
8000
7000
6000
5000
4000
3000
-4
-3
-2
-1
0
1
2
3
Ab (nM)
9D4 (IC50 = 0.04nM)
R347 (IgG1 isotype control)

Figure 25



A
Spleen
% B220+/Ly6C+ cells
B
LN
% B220+/Ly6C+ cells
C
Blood
% B220+/Ly6C+ cells
D
BM
% B220+/Ly6C+ cells
Adv
PBS
MuIgG
a-INFAR
Adv-IFNα

Figure 26



9D4-wt
9D4-IgG1-TM
9D4-IgG4-DM
OVA
Resp. Diff.(RU)
Time(sec)
60
53
46
39
32
25
18
11
4
-3
-10
0
400
800
1200
1600
2000
2400
2800
3200
3600
4000

Figure 27A



Fc-gamma-R-I vs 9D4-wt
OVA vs. 9D4-wt
Resp. Diff.(RU)
1390
1190
990
790
590
390
190
-10
0
600
1200
1800
2400
3000
3600
4200
4800
5400
6000
Time(sec)

Figure 27B



Fc-g-R-I vs. 9D4-IgG4-DM
OVA vs.9D4-IgG4-DM
Resp. Diff.(RU)
Time(sec)
500
470
440
410
380
350
320
290
260
230
200
170
140
110
80
50
20
-10
0
600
1200
1800
2400
3000
3600
4200
4800
5400
6000

Fig 27C



Fc-g-R-I vs. 9D4-IgG1-TM
OVA vs. 9D4-IgG1-TM
Resp. Diff.(RU)
Time(sec)
500
470
440
410
380
350
320
290
260
230
200
170
140
110
80
50
20
-10
0
600
1200
1800
2400
3000
3600
4200
4800
5400
6000

Figure 28



Fold Change(Kidney)
20
15
10
5
0
Adv(-)
Mouse IgG
IFNAR Ab
ICAM1
VCAM1
CXCL9
CXCL10
IFIT1
**
***
Kidney Taqman Assay on Wk 8 Samples

Figure 29





Week 7
Anti-dsDNA(μg/ml)
0
1
2
3
4
5
6
7
Adv-
Mouse IgG
IFNAR Ab
Adv-IFNa
Anti-ds DNA (ug/ml)
weeks
1
2
3
4
5
6
7
8
Adv-IFN α +mouse Ig
Adv-IFN α + IFNAR Ab
Adv

Figure 30



• Score 1.5 = 300mg/dL, score 2.0 = 500 mg/dL, Score 3.5 = Animal death

Figure 31



Tx	% Death at wk 5	% No Proteinuria at wk 5
Adv-IFNa + PBS	7/8 (87.5 %)	0/8 (0%)
Adv-IFNa + Mouse IgG	5/8 (62.5%)	0/8 (0%)
Adv-IFNa + IFNAR Ab	0/8 (0%)	5/10 (50%)

Figure 32




Fig 33.





Fig. 34


Absorbance (490nM)
0.45
0.40
0.35
0.30
0.25
0.20
Max
Minimum
-2
-1
0
1
2
3
nM Ab
+ve control
R347 TM
9D4-TM